相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis
Luis Hernandez et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
Duygu Bozkaya et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA
Daniel M. Hartung
NEUROTHERAPEUTICS (2017)
The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
Wenqing Su et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States
Luis Hernandez et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Brain health: time matters in multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective
Julie Chevalier et al.
PLOS ONE (2016)
Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom
Felicity Allen et al.
VALUE IN HEALTH (2015)
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England
Maciej J. Maruszczak et al.
JOURNAL OF MEDICAL ECONOMICS (2015)
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-beta(1a) in Relapsing-Remitting Multiple Sclerosis
Xinke Zhang et al.
CNS DRUGS (2015)
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden
Ken O'Day et al.
JOURNAL OF MEDICAL ECONOMICS (2015)
Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches
Shien Guo et al.
PHARMACOECONOMICS (2014)
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study
Josep Darbà et al.
JOURNAL OF MEDICAL ECONOMICS (2014)
Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
Carole Dembek et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
Joel P. Thompson et al.
PHARMACOECONOMICS (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review
Leonardo Koeser et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2013)
Implications of Real-world Adherence on Cost-effectiveness Analysis in Multiple Sclerosis
David W. Brandes et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
Shekoufeh Nikfar et al.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis
Annie Hawton et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2013)
Cost-Effectiveness of Early Initiation of Fingolimod Versus Delayed Initiation After 1 Year of Intramuscular Interferon Beta-1a in Patients with Multiple Sclerosis
Neetu Agashivala et al.
CLINICAL THERAPEUTICS (2012)
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States
Feng Pan et al.
CLINICAL THERAPEUTICS (2012)
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States
Soyon Lee et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients
Rainel Sánchez-de la Rosa et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Cost-effectiveness of disease-modifying therapy for multiple sclerosis A population-based study
K. Noyes et al.
NEUROLOGY (2011)
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis
Ken O’Day et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Multiple sclerosis: Geoepidemiology, genetics and the environment
Ron Milo et al.
AUTOIMMUNITY REVIEWS (2010)
A Health-Economic Evaluation of Disease-Modifying Drugs for the Treatment of Relapsing-Remitting Multiple Sclerosis From the German Societal Perspective
Mark Nuijten et al.
CLINICAL THERAPEUTICS (2010)
What Is Value in Health Care?.
Michael E. Porter
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Chemotherapeutics in the treatment of multiple sclerosis
Bernd C. Kieseier et al.
Therapeutic Advances in Neurological Disorders (2010)
Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis
Evelyn Chiao et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a Modelling the Clinical and Economic Implications
Shien Guo et al.
PHARMACOECONOMICS (2009)
Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population
Paul Tappenden et al.
VALUE IN HEALTH (2009)
Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition
Slobodan M. Jankovic et al.
VOJNOSANITETSKI PREGLED (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
The cost effectiveness and budget impact of natalizumab for formulary inclusion
Justin Bakhshai et al.
JOURNAL OF MEDICAL ECONOMICS (2009)
Cost Effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis
Stephanie Earnshaw et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2009)
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
G. Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Cost-effectiveness analyses of natalizumab (Tysabri (R)) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK
Ray Gani et al.
PHARMACOECONOMICS (2008)
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: Lessons for inferring generalizability
M Barbieri et al.
VALUE IN HEALTH (2005)
Development and validation of a grading system for the quality of cost-effectiveness studies
CF Chiou et al.
MEDICAL CARE (2003)
分享论文
